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ay 6, 2013.he purpose of this study was to investigate the risk of thrombosis and bleeding according to multiple
antithrombotic treatment regimens in atrial ﬁbrillation (AF) patients after myocardial infarction (MI) or percutaneous
coronary intervention (PCI).Background The optimal antithrombotic treatment strategy is unresolved in patients with multiple indications.Methods A total of 12,165 AF patients hospitalized with MI and/or undergoing PCI between 2001 and 2009 were identiﬁed
by nationwide registries (60.7% male; mean age 75.6 years). Risk of MI/coronary death, ischemic stroke, and
bleeding according to antithrombotic treatment regimen was estimated by Cox regression models.Results Within 1 year, MI or coronary death, ischemic stroke, and bleeding events occurred in 2,255 patients (18.5%), 680
(5.6%), and 769 (6.3%), respectively. Relative to triple therapy (oral anticoagulation [OAC] plus aspirin plus
clopidogrel), no increased risk of recurrent coronary events was seen for OAC plus clopidogrel (hazard ratio [HR]:
0.69, 95% conﬁdence interval [CI]: 0.48 to 1.00), OAC plus aspirin (HR: 0.96, 95% CI: 0.77 to 1.19), or aspirin plus
clopidogrel (HR: 1.17, 95% CI: 0.96 to 1.42), but aspirin plus clopidogrel was associated with a higher risk of
ischemic stroke (HR: 1.50, 95% CI: 1.03 to 2.20). Also, OAC plus aspirin and aspirin plus clopidogrel were associated
with a signiﬁcant increased risk of all-cause death (HR: 1.52, 95% CI: 1.17 to 1.99 and HR: 1.60, 95% CI: 1.25 to
2.05, respectively). When compared to triple therapy, bleeding risk was nonsigniﬁcantly lower for OAC plus
clopidogrel (HR: 0.78, 95% CI: 0.55 to 1.12) and signiﬁcantly lower for OAC plus aspirin and aspirin plus clopidogrel.Conclusions In real-life AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel was equal
or better on both beneﬁt and safety outcomes compared to triple therapy. (J Am Coll Cardiol 2013;62:981–9)
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13; revised manuscript received April 4, 2013,ﬁbrillation (AF) (1), whereas dual antiplatelet therapy is
indicated for acute coronary syndrome (ACS) and after
percutaneous coronary intervention (PCI) (2,3). Although
triple therapy including OAC, aspirin, and clopidogrel is
recommended for AF patients with ACS and/or PCI,
evidence stems from small observational studies of mostlySee page 990single center origin, and American and European position
documents categorize recommendations as Level of Evi-
dence: C (4,5). Consequently, guidelines emphasize the need
for individualization of treatment in respect to careful
assessment of each patient’s risk of thrombosis and bleeding
to ﬁnd the optimal balance between risk and beneﬁt of
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982treatment. A recent study showed
that initiation of triple therapy is
immediately associated with in-
creased and persistent bleeding
risk compared to OAC plus a
single antiplatelet agent (6). The-
refore, a thorough exploration of
a less-is-more approach is crucial
as no ﬁrm knowledge exists on the
effectiveness of adding 2 and not 1
antiplatelet agent on top of OAC.
We performed a nationwide
study of real-world AF patients
who were admitted with my-
ocardial infarction (MI) or un-dergoing PCI, to evaluate the beneﬁt and safety with
multiple antithrombotic drugs. We hypothesized that the
combination of OAC and a single antiplatelet (either aspirin
or clopidogrel) is equal to triple therapy concerning
thromboembolic protection, bleeding, and death.Methods
The registries. In Denmark, all residents are provided with
a unique and permanent civil registration number that
enables linkage among 4 nationwide administrative registries
(7). First, the Danish National Patient Registry keeps
records of all hospital admissions since 1978 and each
hospitalization is coded with 1 primary diagnosis and, if
appropriate, 1 or more secondary diagnoses, according to the
International Classiﬁcation of Diseases-8th Revision (ICD-
8; until 1994) and 10th Revision (ICD-10; from 1994). The
registry also includes surgical and procedural treatment
classiﬁcation codes since 1996 (Nordic Medical Statistics
Committees Classiﬁcation of Surgical Procedures). Second,
the Danish Registry of Medicinal Product Statistics
(national prescription registry) contains information on all
drug prescriptions dispensed from pharmacies in Denmark
since 1995. All drugs are classiﬁed according to the inter-
national Anatomical Therapeutical Chemical (ATC) clas-
siﬁcation system. Finally, through the National Causes of
Death Register and the Civil Registration System, both vital
status and causes of death were obtained. The former holds
information about the immediate, contributory, and
underlying causes of death. These registries are complete for
any Danish resident ages 10 years or above on January 1,
1997. (All ICD and ATC codes used are available in the
Online Tables 1 and 2, respectively.)
Population. Among subjects with a previous diagnosis of
AF, we identiﬁed patients hospitalized for MI or PCI
between January 1, 2001, and December 31, 2009 (Fig. 1).
We excluded patients with an admission for MI/PCI within
1 year before the index date. A 7-day quarantine period was
deﬁned at discharge to disregard patients with unmeasured
complications during index admission, as done previously
(6). The inclusion date was therefore 7 days after discharge,and inclusion criteria were prescription of antithrombotic
treatment at baseline in subjects alive, age 30 years or older,
and no diagnosis of bleeding, MI, or thromboembolism
during the quarantine period. The diagnosis of MI has been
validated with a speciﬁcity of 93% (8), and the positive
predictive value of AF is 99% (9).
Antithrombotic treatment regimens. We collected infor-
mation on warfarin and phenprocoumon to categorize OAC
as these were the only available OACs in Denmark during the
study period. Similarly, aspirin and clopidogrel were the
antiplatelets used in the majority of cases. Prasugrel, ticagrelor,
and newer anticoagulants were not approved for routine use in
AF or coronary artery disease patients in Denmark during the
study period. We classiﬁed the following 4 multiple antith-
rombotic treatment regimens: aspirin plus clopidogrel (dual
antiplatelet therapy); OAC plus aspirin; OAC plus clopi-
dogrel; and OAC plus aspirin plus clopidogrel (triple therapy).
Monotherapies with aspirin, clopidogrel, and OAC were also
identiﬁed. Antithrombotic treatment at baseline was calcu-
lated as drug availability within 30 days from discharge, as
done previously (10). To only consider patients at risk if
treated, for every prescription dispensed the applicable treat-
ment regimen was calculated for each patient. In brief, the
daily dosage was estimated for up to 3 consecutive prescrip-
tions. This enabled us to calculate any treatment regimen at
any given time from prior claimed prescriptions. Hence,
patients were only deemed at risk when exposed to treatment,
and their treatment regimen was continually updated (11,12).
Outcomes. Beneﬁt outcomes were deﬁned as MI or
coronary death, fatal or nonfatal ischemic stroke (including
transient ischemic attack), and all-cause mortality. Safety
outcome was fatal or nonfatal bleeding (e.g., intracranial
bleeding and gastrointestinal bleeding). (The full list is
available in Online Table 3.) Nonfatal events were obtained
from admissions in the National Patient Registry, and fatal
events were recorded from National Causes of Death
Register. If a nonfatal event was followed by death within 1
week, the event was recorded as fatal. Ischemic stroke has
been validated in the registries (13). The diagnoses to
characterize serious bleeding have previously been used
(6,10,11), and bleeding diagnoses have shown a positive
predictive value of 89% to 99% in hospital databases (14).
Compared to other clinical deﬁnitions of bleeding (15), our
deﬁnition did not include data on hemoglobin levels or
transfusions, but also did not include minor bleedings not
serious enough to result in hospitalization.
Comorbidity and concomitant therapy. Comorbidities of
previous bleeding, hypertension, congestive heart failure,
ischemic stroke, transient cerebral ischemia, systemic em-
bolus, renal/liver failure, peripheral arterial disease, alcohol
abuse, and diabetes mellitus were determined from the
registries as previously described (16). Scores of HAS-
BLED (hypertension, abnormal renal/liver function,
stroke/thromboembolism, bleeding history, labile interna-
tional normalized ratio, elderly [age >65 years], and drug
consumption/alcohol abuse), CHADS2 (congestive heart
Figure 1 Selection of the Study Population
MI ¼ myocardial infarction; OAC ¼ oral anticoagulant; PCI ¼ percutaneous coronary intervention; TCI ¼ transient cerebral ischemia.
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983failure, hypertension, age 75 years, diabetes mellitus,
stroke/transient ischemic attack), and CHA2DS2-VASc
(adding vascular disease, age 65 to 75 years, and female sex)
were calculated. Of note, data on labile international
normalized ratio was unobtainable and use of antiplatelet
therapy was omitted from the “modiﬁed” HAS-BLED score
because it is an explanatory variable. All scores have formerly
been conﬁrmed to accurately predict risk of thromboembo-
lism and bleeding in the Danish population (12).
Statistical analyses. Patient characteristics according to
treatment regimen at baseline are expressed as percentages or
as means and standard deviations. Crude incidence rates
(events per 100 person-years) were calculated within 1 year
according to treatment regimen exposure (time-varying
exposure). The Cox proportional hazard model was used to
estimate the risk between dual and triple therapy regimens.
Dual antiplatelet therapy was used as an active comparator for
reference as this comprised the largest group and the standard
of care for an acute coronary event. In the comparison analysis,
we used triple therapy for reference as this is the recommended
initial treatment. The analyses were adjusted for age, sex,
inclusion year, and inclusion status (MI/PCI); and HAS-
BLED and CHADS2 scores also were used for outcomes of
bleeding and ischemic stroke, respectively. Subjects were
followed up for 1 year, and censored if they died or at end of
follow-up on December 31, 2009. The assumptions of the
Cox model (proportional hazard assumption, linearity of
continuous variables, and lack of interactions) were tested, andthe models were found valid unless otherwise indicated. A 2-
sided signiﬁcance level of 0.05 was used.
The following sensitivity analyses were performed. A
Cox model where baseline treatment regimen was used as
non–time-dependent exposure (intention-to-treat analysis),
and a Cox model to investigate the effect of a nonfatal
bleeding, ischemic stroke, or MI admission on subsequent
mortality. A nonfatal episode was incorporated as time-
varying variable; for example, a subject was considered in
the nonbleeding group before the date of nonfatal bleeding
episode and thereafter included in the bleeding group. This
model was adjusted for antithrombotic treatment, age, sex,
inclusion year, and inclusion status. As suggested by Ray
(17), we decided on a sensitivity analysis using a new-user
design, and excluded prevalent users of aspirin and clopi-
dogrel (i.e., any subscription claims within 6 months before
index MI/PCI), whereas OAC use was allowed because we
did not want to exclude ongoing use in AF patients before
inclusion. We also did a Cox model including patients in the
quarantine period with 90 days of follow-up. To ensure
consistency of the results in the PCI group, we did separate
analyses of absolute risk due to the group being considered as
“low risk” patients before start of the study. All analyses were
performed with SAS version 9.2 (SAS Institute, Cary,
North Carolina) and Stata version 11.0 (StataCorp, Chi-
cago, Illinois).
Ethics. Register-based studies do not require ethical approval
in Denmark as patients cannot be identiﬁed. The Danish Data
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984Protection Agency approved the study (reference no. 2007-58-
0015, international reference: GEH-2010-001).Results
A total of 12,165 patients was included in the study (Fig. 1)
with a mean age of 75.6  10.3 years, and 60.7% were male.
Mean CHADS2, CHA2DS2-VASc, and HAS-BLED
scores were 1.9  1.2, 4.0  1.6, and 2.0  0.9, respec-
tively. Baseline characteristics are shown in Table 1. Nearly
two-thirds were treated with multiple antithrombotic drugs
at baseline (62.0%), and a total of 4,659 (38.3%) received
OAC. Only 121 (<1%) had a CHA2DS2-VASc score of 0.
Figure 2 shows that according to predicted risk of eitherTable 1 Baseline Characteristics According to Antithrombotic Treatm
Monotherapy
Aspirin or Clopidogrel or OAC
(n ¼ 4,627)
Aspirin þ Clopido
(n ¼ 3,590)
MI as inclusion criteria 4,173 (90.2) 2,581 (71.9)
With PCI within 1 day* 162 (3.9) 571 (22.1)
With PCI within 2 to 7days* 72 (1.7) 215 (8.3)
PCI as inclusion criteria 454 (9.8) 1,009 (28.1)
With stent implantation* 294 (65.8) 835 (82.8)
Male 2,446 (52.9) 2,219 (61.8)
Age
Male, yrs 75.3  10.8 72.1  10.7
Female, yrs 80.8  9.6 78.3  9.7
CHADS2 score
Low (0) 406 (8.8) 443 (12.3)
Intermediate (1) 1,196 (25.9) 1,126 (31.4)
High (2) 3,025 (54.4) 2,021 (56.3)
CHA2DS2-VASc score
Low (0) 30 (0.7) 52 (1.5)
Intermediate (1) 185 (4.0) 274 (7.6)
High (2) 4,412 (95.4) 3,264 (90.9)
HAS-BLED
Low (0–1) 159 (3.4) 172 (4.8)
Intermediate (2) 3,081 (66.6) 2,546 (70.9)
High (3) 1,387 (30.0) 872 (24.3)
Comorbidity
Previous ischemic stroke 628 (13.6) 360 (10.0)
Previous bleeding 563 (12.2) 257 (7.2)
Heart failure 1,533 (33.1) 807 (22.5)
Hypertension 2,894 (62.6) 2,416 (67.3)
Potential valvular AF 512 (11.1) 344 (9.6)
Concomitant treatment
RAS inhibitors 2,363 (51.1) 2,033 (56.6)
Beta-blockers 2,920 (63.1) 2,744 (76.4)
Statins 1,855 (40.1) 2,604 (72.5)
Antiarrhythmic drugsy 4,089 (88.4) 3,279 (91.3)
Glucose-lowering drugs 700 (15.1) 528 (14.7)
Steroids 570 (12.3) 370 (10.3)
NSAID 1,251 (27.0) 765 (21.3)
PPI 981 (21.2) 1,003 (27.9)
Values are n (%) or mean  SD. For descriptions of HAS-BLED, CHADS2, and CHA2DS2-VASc scores, ple
drugs, calcium-channel blockers, and amiodarone.
AF ¼ atrial ﬁbrillation; MI ¼ myocardial infarction; NSAID ¼ nonsteroidal anti-inﬂammatory drug; OA
RAS ¼ renin-angiotensin system.ischemic stroke (CHADS2) or bleeding (HAS-BLED), the
type of antithrombotic treatment regimen prescribed at
baseline was fairly consistent regardless of increasing score.
During the study period of 1 year, a total of 2,255 (18.5%),
680 (5.6%), and 769 (6.3%) patients were registered with
MI/coronary death, ischemic stroke, and bleeding, respec-
tively. A total of 2,356 (19.4%) of the patients died. Table 2
shows crude rates and hazard ratio (HR) for all outcomes.
Bleeding rates increased with increased intensity of
treatment.
Triple therapy versus dual therapy. Figure 3 shows com-
parisons of dual antiplatelet therapy, OAC plus clopidogrel,
and OAC plus aspirin versus triple therapy. Relative to triple
therapy, a nonsigniﬁcant beneﬁt for MI or coronary deathent Regimen
Dual Therapy Triple Therapy
grel OAC þ Aspirin
(n ¼ 1,504)
OAC þ Clopidogrel
(n ¼ 548)
OAC þ Aspirin þ Clopidogrel
(n ¼ 1,896)
1,359 (90.4) 262 (47.8) 1,013 (53.4)
47 (3.1) 59 (10.8) 309 (16.3)
15 (1.0) 25 (4.6) 131 (6.9)
145 (9.6) 286 (52.2) 883 (46.6)
62 (42.8) 243 (85.0) 794 (90.0)
917 (61.0) 402 (73.4) 1,401 (73.9)
74.3  9.1 71.4  9.0 71.3  8.8
78.9  7.9 75.7  8.5 76.2  7.9
122 (8.1) 43 (7.9) 203 (10.7)
348 (23.1) 158 (28.8) 550 (29.0)
1,034 (68.8) 347 (63.3) 1,143 (60.3)
4 (0.3) 7 (1.3) 28 (1.5)
42 (2.8) 44 (8.0) 160 (8.4)
1,458 (96.6) 497 (90.7) 1,708 (90.1)
45 (3.0) 15 (2.7) 64 (3.4)
1,051 (69.9) 380 (69.3) 1,360 (71.7)
408 (27.1) 153 (27.9) 472 (24.9)
222 (14.8) 63 (11.5) 190 (10.0)
131 (8.7) 51 (9.3) 116 (6.1)
524 (34.8) 165 (30.1) 512 (27.0)
1,066 (70.9) 419 (76.5) 1,464 (77.2)
216 (14.4) 73 (13.3) 234 (12.3)
943 (62.7) 371 (67.7) 1,277 (67.4)
1,095 (72.8) 408 (74.5) 1,532 (80.8)
812 (54.0) 403 (73.5) 1,504 (79.3)
1,408 (93.6) 517 (94.3) 1,808 (95.4)
270 (18.0) 98 (17.9) 322 (17.0)
133 (8.8) 47 (8.6) 148 (7.8)
262 (17.4) 111 (20.3) 380 (20.0)
351 (23.3) 123 (22.5) 418 (22.1)
ase see text. *Group percentages given. yIncluding beta-blockers, digoxin, class 1C antiarrhythmic
C ¼ oral anticoagulant; PCI ¼ percutaneous coronary intervention; PPI ¼ proton pump inhibitors;
Figure 2 Initial Antithrombotic Treatment and Crude Rates of Ischemic Stroke and Bleeding According to Predicted Risk
Crude rates are events per 100 person-years. For deﬁnitions of CHADS2 score and HAS-BLED score, please see text. OAC ¼ oral anticoagulant.
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985was seen for OAC plus clopidogrel (HR: 0.69, 95% conﬁ-
dence interval (CI): 0.48 to 1.00), whereas OAC plus aspirin
(HR: 0.96, 95% CI: 0.77 to 1.19), or dual antiplatelet
therapy (HR: 1.17, 95% CI: 0.96 to 1.42) were comparable.
For ischemic stroke only dual antiplatelet therapy showed a
higher risk (HR: 1.50, 95% CI: 1.03 to 2.20). When
compared to triple therapy, bleeding risk was nonsigniﬁcantly
lower for OAC plus clopidogrel (HR: 0.78, 95% CI: 0.55 to
1.12) and signiﬁcantly lower for OAC plus aspirin (HR:
0.69, 95% CI: 0.53 to 0.90), and dual antiplatelet therapy
(HR: 0.48, 95% CI: 0.38 to 0.61). OAC plus aspirin and
dual antiplatelet therapy were associated with signiﬁcant
increased risk of all-cause death (HR: 1.52, 95% CI: 1.17 to
1.99 and 1.60, 95% CI: 1.25 to 2.05), respectively, whereas
OAC plus clopidogrel was not (HR: 0.87, 95% CI: 0.56 to
1.34). Cause of death was equally distributed between the
different antithrombotic treatment regimens (Online Fig. 1).
Approximately 50% of all deaths were cardiovascular-related
deaths.
Sensitivity analyses. Baseline treatment regimen as a
non–time-dependent variable showed similar estimates of
outcomes as in the main analyses (Online Fig. 2). We
investigated the effect on subsequent mortality after admis-
sion for a nonfatal episode of bleeding, and 181 (26%) of 691
patients with an admission for nonfatal bleeding died
compared to 2,175 (19%) of 11,474 without nonfatal
bleeding (HR: 2.79, 95% CI: 2.39 to 3.26). Estimates for
episodes of nonfatal myocardial infarction and nonfatal
ischemic stroke were HR 3.17 (95% CI: 2.84 to 3.55) and
HR 3.93 (95% CI: 3.37 to 4.57), respectively. A total of5,065 patients was examined using the new-user design, and
the crude incidence rate and HR of the beneﬁt and safe-
ty outcomes were similar to our main analysis (Online
Table 3). Including the quarantine period, we followed up
13,007 patients for 90 days and risk estimates were compa-
rable to the main analyses for all outcomes. Relative to triple
therapy, no increased risk of MI/coronary death for OAC
plus clopidogrel (HR: 0.78, 95% CI: 0.51 to 1.17) and OAC
plus aspirin (HR: 1.17, 95% CI: 0.92 to 1.49) were observed.
We did not ﬁnd any interactions between various subgroups;
age75 years,<75 years, sex, PCI, or MI status at inclusion.
PCI-only patients (without MI) had considerably lower
absolute risk for MI or coronary death, with crude incidence
rates of 6.2, 3.0, 5.2, and 6.5 events per 100 person-years for
triple therapy, OAC plus clopidogrel, OAC plus aspirin, and
dual antiplatelet therapy, respectively. The crude incidence
rates for ischemic stroke and bleeding in PCI-only patients
were comparable to the overall population (data not shown).
Discussion
Our main ﬁnding was that in AF patients after MI/PCI, the
combination of OAC plus clopidogrel is comparable to the
recommended triple therapy in respect to the prevention of
thromboembolic outcomes of MI/coronary death and
ischemic stroke while the risk of bleeding was similar.
Notably, the risk of all-cause mortality was similar between
OAC plus clopidogrel and triple therapy but markedly
increased for other therapies, namely, OAC plus aspirin and
dual antiplatelet therapy. No beneﬁcial effect was evident for
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986adding aspirin to OAC plus clopidogrel treatment, which
challenges current recommendations that favors triple
therapy for this population.
The present recommendation of triple therapy for patients
with recent MI and/or PCI and concurrent AF is estab-
lished because of OAC being indicated for AF patients with
stroke risk factors and dual antiplatelet therapy being indi-
cated after ACS or PCI (1,18–20). Nonrandomized studies
on triple therapy shows a protection from ischemic events
with no clear excess bleeding, compared to other regimens
(21,22), but the studies all have limitations of being
potentially underpowered, performed in single center
settings, and only including patients after stent implantation.
Our ﬁndings of a potential safer proﬁle of a single anti-
platelet added to OAC is in line with Nguyen et al. (23),
who followed up 800 patients after coronary stenting but
irrespective of presence of atrial ﬁbrillation for 6 months,
and did not ﬁnd a difference between single or dual anti-
platelet approach combined with warfarin. Our data also
suggest that the favored antiplatelet to be used in combi-
nation with OAC could be clopidogrel, and this combina-
tion may well be used in AF patients after recent MI and/or
PCI. A case-control study of patients after coronary stenting
with or without an indication for long-term OAC (being
AF in 70% of cases) also found more favorable outcomes for
clopidogrel than aspirin in combination with OAC (24),
whereas another study found a protective effect of coumarins
on a combined endpoint of major adverse cardiovascular
events and death compared to non–coumarin-treated AF
patients with stent implantation (25). The latter study was
limited by being based on post-discharge telephone inter-
views and post-hoc collection of outcome data.
Results are available from the recently published WOEST
(What Is the Optimal Antiplatelet and Anticoagulant
Therapy in Patients With Oral Anticoagulation and Coro-
nary Stenting) trial, which was a randomized prospective
multicenter study of stented patients on chronic OAC (AF
and non-AF patients), testing triple therapy versus OAC
plus clopidogrel (26). Albeit with different inclusion criteria
and lower numbers (total inclusion of 573 subjects)
compared to our study, the WOEST investigators found
similar cardiovascular protection for a combined endpoint of
death, stroke, MI, target vessel revascularization, and stent
thrombosis after 1 year. A signiﬁcantly lower rate of death
and nonsigniﬁcantly lower numbers of MI with OAC plus
clopidogrel were also present in the WOEST study, which
is in concordance with our ﬁndings. However, the lower
risk for bleeding for OAC plus clopidogrel was primarily
driven by minor bleeding events, whereas our study only in-
cluded bleedings serious enough to warrant hospitalization.
Importantly, the poor prognosis found in both the WOEST
trial and in the present study with triple therapy could be
related to bleeding events, for example, withdrawal of life-
saving thromboprophylactic medication or higher case
fatality rates than previously assumed. Future studies on the
complications of bleeding (minor or major) could provide
Figure 3 Beneﬁt and Safety With Triple Therapy Versus Dual Therapies
Triple therapy (oral anticoagulant [OAC] plus aspirin plus clopidogrel [dotted line]) is used as reference (hazard ratio ¼1.00). Orange circles indicate OAC plus clopidogrel;
yellow circles indicate OAC plus aspirin; green circles indicate aspirin plus clopidogrel. MI ¼ myocardial infarction.
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987a better understanding on the use of multiple antithrombotic
drugs. While awaiting further studies supportive of the
WOEST trial, together with our results, the evidence of
beneﬁt when adding aspirin to OAC and clopidogrel seems
to diminish.
Another important ﬁnding was that antithrombotic treat-
ment prescribed initially was not markedly inﬂuenced by
either predicted stroke risk or bleeding risk. Every day
prescription of antithrombotic treatment is known to show
high variability (27), and these ﬁndings are suggestive of
under-treatment when only approximately 40% received
treatment that included OAC. Especially worrisome is it
when increased CHADS2 and HAS-BLED scores are clearly
related to increased rates of ischemic stroke and bleeding,
respectively (Fig. 2). This message of a seemingly random
treatment of patients and simple risk scoring schemes that
predict risk should be acknowledged by physicians.
As newer OACs (e.g., apixiban, rivaroxiban, dabigatran)
are likely to replace vitamin K antagonists in certain AF
patients in the years to come, clinicians will soon face new
treatment possibilities not fully explored in trials or in large
databases. While no head-to-head comparison of these new
agents is available, some data on triple therapy with these
newer OAC are available. In post–acute coronary syndrome
patients (presence of AF not known), the addition of
apixaban to dual antiplatelet therapy did no better with
thromboembolic outcomes but resulted in increased serious
bleeding compared to placebo (28). With rivaroxiban, in
very low dosage twice-a-day regimen, there was a reduction
of thromboembolic complications but at the cost of more
nonfatal bleedings (29). A substudy of the RE-LY(Randomized Evaluation of Long-Term Anticoagulation
Therapy) trial showed even further increased bleeding risk
with dual antiplatelet on top of dabigatran than a single
antiplatelet (30). Unfortunately, no data were reported for
the effect of the number or type of antiplatelets for stroke or
coronary events, although up to 40% of patients had coro-
nary artery disease.
Study strengths and limitations. The main strength of this
study is the possibility to evaluate the effect of antithrombotic
therapy in real-life patients in a nationwide setting regardless
of race, employment, health insurance coverage, and socio-
economic status. We compared clinically used regimens that
would not be feasible in a controlled environment or from
single center studies. We also were able to update treatment
on a continual basis, which is often a concern when esti-
mating bleeding endpoints (31). The diagnoses of AF,
ischemic stroke, and MI are all validated in the registries
(8,9,13), and using only hospitalized bleeding events, we
presume we only collect serious bleeding outcomes. The
combination of OAC plus aspirin shows similar estimates for
coronary, stroke, and bleeding events compared to OAC plus
clopidogrel and triple therapy, but did, however, also show
markedly higher risk of death, hence confounding by indi-
cation could have affected our results. To estimate the
potential effect of confounding by indication, we used a new-
user design as a sensitivity analysis (17). The results were
consistent with the main analyses, indicating that our esti-
mates were robust and not likely confounded by a “healthy
antithrombotic user” effect (Online Table 3). Furthermore, if
confounding by indication was related to the prescription of
either aspirin or clopidogrel, then results for triple therapy
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988would also be affected. Initial antithrombotic treatment did
not seem to be inﬂuenced by either predicted stroke or
bleeding risk (Fig. 2), and we also found no differences
between treatment regimen at time of death and cause of
death (Online Fig. 1). Moreover, any bias is most likely to
affect our estimates conservatively, namely, intensive rec-
ommended triple therapy is most likely to be prescribed to
healthier patients with a better outcome proﬁle. Although we
have controlled for clinically relevant covariates including
validated risk scoring schemes for stroke and bleeding, the
possibility of residual confounding from unmeasured vari-
ables remains. We did not have access to data on body mass
index, smoking status, or international normalized ratio
values. Concerning the latter, compared to other countries
but in a controlled setting, time-in-therapeutic range is high
in Denmark (>70%) (32). The use of over-the-counter
aspirin could not be identiﬁed in the registries, but as
persistence to therapy in aMI population in Denmark is high
and because of ﬁnancial reimbursement, we believe the usage
is negligible (10).
Conclusions
In real-life AF patients with indications for multiple
antithrombotic drugs after MI/PCI, OAC and clopidogrel
was equal or better on both beneﬁt and safety outcomes
compared to triple therapy. Our data suggest that triple
therapy management regimens might be replaced by OAC
and clopidogrel without any additional risk of recurrent
thrombotic events and a lower risk of bleeding. Data from
large randomized studies are severely needed to estimate
overall beneﬁt.
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